APUS - Apimeds Pharmaceuticals US, Inc.
Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
---|---|---|---|---|---|---|---|
1.95 -0.2 (-10.16%) | --- | --- | 0.0 (0.1%) | --- | --- | -0.2 (-10.16%) | -0.2 (-10.16%) |
Apimeds Pharmaceuticals Us Inc is a clinical-stage company. It is engaged in a pharmaceutical business that provides the biological drug Apitox to clients in the biological drug commercial transaction area. It are a clinical stage biopharmaceutical company in the process of developing Apitox, an intradermally administered bee venom-based toxin. Company focus is on developing therapies that address inflammation and pain management symptoms associated with knee OA and, to a lesser extent, MS. Apitox is currently marketed and sold by Apimeds Inc. in South Korea as Apitoxin for the treatment of OA.
Category:
PHARMACEUTICAL PREPARATIONS
Market Period:
Closed
Earnings & Ratios
- Basic EPS:
- -0.26
- Diluted EPS:
- -0.26
- Basic P/E:
- -6.7377
- Diluted P/E:
- -6.7377
- RSI(14) 1m:
- 0.89
- VWAP:
- 1.75
- RVol:
Events
Period | Kind | Movement | Occurred At |
---|---|---|---|
Day | Price decrease day | 1.75 -0.2 (-10.25%) | Oct 14 19:24 |